| Literature DB >> 23812853 |
Jarosław Szulfer1, Alina Plenis, Tomasz Bączek.
Abstract
This paper investigates the performance of a column classification system developed at the Katholieke Universiteit Leuven applied to pharmaceutical chromatographic analyses. The liquid chromatography assay of lamotrigine and related compounds was carried out according to the method prescribed in the European Pharmacopoeia monograph, using 28 brands of stationary phases. A ranking was built based on the F KUL value calculated against the selected reference column, then compared with the column test performance established for the stationary phases studied. Therefore, the system suitability test prescribed by the European Pharmacopoeia in order to distinguish between suitable or unsuitable columns for this analysis was evaluated. Moreover, it was examined whether the classes of the stationary phases, determined using test parameter results, contain either suitable or unsuitable supports for the lamotrigine separation. This assay was performed using chemometric a technique, namely factor analysis.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23812853 PMCID: PMC3713273 DOI: 10.1007/s00216-013-7097-5
Source DB: PubMed Journal: Anal Bioanal Chem ISSN: 1618-2642 Impact factor: 4.142
Fig. 1Chemical structure of a lamotrigine, b impurity A, c impurity B, d impurity C, e impurity D, f impurity E, g impurity F, and h impurity G
List of C18 RP-LC tested stationary phases and their specifications as provided by the manufacturer
| Number of the column | Name of the column | Manufacturer/ supplier | Carbon load [%] | Pore size [Å] | Surface Area [m2/g] | Silica | Endcap. | Abbreviation |
|---|---|---|---|---|---|---|---|---|
| 1 | Hypersil BDS C18 | Thermo | 11 | 130 | 170 | A | + | HYB |
| 2 | Hypersil Elite C18 | Thermo | 15 | 114 | 250 | A | + | HYE |
| 3 | Xbridge C18 | Waters | 18 | 130 | 185 | B | + | XBC18 |
| 4 | Discovery C18 | Supelco | 12 | 180 | 200 | B | + | DISC |
| 5 | ACE 5 C18 | ACT | 15.5 | 100 | 300 | B | + | AC18 |
| 6 | ACE 5 C18-AR | ACT | 15.5 | 100 | 300 | B | + | AAR |
| 7 | Inertsil ODS2 | GL Science | 18.5 | 150 | 320 | B | + | ING |
| 8 | Nucleosil 100–5 C18 HD | Macherey-Nagel | 20 | 100 | 350 | A | + | NUH |
| 9 | ACE 5 AQ | ACT | 14 | 100 | 300 | EP | + | AAQ |
| 10 | Wakosil II 5 C18 HG | SGE | 15 | 120 | 300 | B | + | WAH |
| 11 | Nucleosil 100–5 C18 Nautilus | Macherey-Nagel | 16 | 100 | 350 | EP | + | NUN |
| 12 | Inertsil ODS2 | Hichrom | 18.5 | 150 | 320 | B | + | INH |
| 13 | YMC Pack ODS-AQ | YMC | 14.1 | 120 | 300 | B | + | YPAQ |
| 14 | Nucleosil 100–5 C18 AB | Macherey-Nagel | 24 | 100 | 350 | A | + | NUA |
| 15 | Aqua C18 | Phenomenex | 15 | 125 | 320 | B | + | AQ18 |
| 16 | Kromasil 100–5 C18 | Akzo Nobel | 19 | 100 | 340 | B | + | KRO |
| 17 | Nucleodur C18 Pyramid | Macherey-Nagel | 14 | 110 | 340 | B | + | NUP |
| 18 | ACE 5 C18-HL | ACT | 20 | 90 | 400 | B | + | AHL |
| 19 | Nucleosil 100–5 C18 | Macherey-Nagel | 15 | 100 | 350 | A | + | NU18 |
| 20 | Prodigy ODS3 | Phenomenex | 15.5 | 100 | 450 | B | + | PODS3 |
| 21 | SunFire C18 | Waters | 16 | 100 | 340 | B | + | SUN |
| 22 | Luna C18 | Phenomenex | 17.5 | 100 | 400 | B | + | LUN |
| 23 | Aquasil C18 | Thermo | 12 | 100 | 310 | EP | + | AQSIL |
| 24 | Zorbax SB-Aq | Agilent | proprietary | 80 | 180 | EP | − | ZSBA |
| 25 | Xbridge Shield RP18 | Waters | 17 | 130 | 185 | EP | + | XBSH |
| 26 | Symmetry Shield RP18 | Waters | 17 | 100 | 335 | EP | + | SYSH |
| 27 | Spherisorb ODS1 | Waters | 6.2 | 80 | 220 | A | − | SODS1 |
| 28 | Spherisorb ODS2 | Waters | 11.5 | 80 | 220 | A | + | SODS2 |
Each column has a length of 150 mm, a diameter of 4.6 mm, and particle size of 5 um
A “traditional,” acidic silica gel, B “high purity,” more neutral silica gel, EP embedded or end-capped polar group
The chromatographic parameters and F KUL values for 28 columns studied provided by the KUL method
| Analytical column | Column parameters |
| The position in the ranking list (column no.) | |||
|---|---|---|---|---|---|---|
|
|
|
|
| |||
| HYB | 3.480 | 1.569 | 0.136 | 5.123 | 0 | 1 |
| HYE | 4.450 | 1.502 | 0.121 | 6.807 | 0.407 | 2 |
| XBC18 | 3.361 | 1.392 | 0.128 | 5.518 | 0.425 | 3 |
| DISC | 2.780 | 1.447 | 0.087 | 4.408 | 0.473 | 4 |
| AC18 | 4.489 | 1.505 | 0.097 | 6.833 | 0.498 | 5 |
| AAR | 3.483 | 1.698 | 0.099 | 8.180 | 0.587 | 6 |
| ING | 5.170 | 1.445 | 0.051 | 8.667 | 0.871 | 7 |
| NUH | 5.099 | 1.482 | 0.093 | 8.049 | 1.157 | 8 |
| AAQ | 2.232 | 1.322 | 0.077 | 7.271 | 1.548 | 9 |
| WAH | 4.913 | 1.353 | 0.070 | 7.422 | 1.567 | 10 |
|
|
|
|
|
|
|
|
| INH | 4.257 | 1.639 | 0.062 | 8.431 | 1.749 | 12 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| KRO | 6.199 | 1.491 | 0.091 | 9.038 | 2.599 | 16 |
| NUP | 4.682 | 1.259 | 0.060 | 9.879 | 2.674 | 17 |
| AHL | 6.369 | 1.535 | 0.087 | 8.950 | 2.786 | 18 |
|
|
|
|
|
|
|
|
| PODS3 | 5.476 | 1.246 | 0.078 | 8.416 | 2.933 | 20 |
| SUN | 5.479 | 1.231 | 0.038 | 9.124 | 3.58 | 21 |
| LUN | 5.509 | 1.172 | 0.050 | 9.012 | 4.036 | 22 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Meaning of symbols is explained in the text. The columns non-suitable for the LC analysis of lamotrigine according to the SST test are indicated in bold. The stationary phases non-suitable for the separation of the analytes according to the second Ph. Eur. recommendation are indicated in italics
Summary of retention data set of p/v and t R, %t RR, and R s for lamotrigine and related substances in column performance test for 28 columns studied
| Substances | SST | Lamotrigine | Impurity A | Impurity B | Impurity C | Impurity D | Impurity E | Impurity F | Impurity G | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. | Analytical column: |
|
| % |
| % |
|
|
|
|
|
|
|
| % |
|
| % |
|
| % |
|
|
| HYB | 6.16 | 6.79 | 97 | 8.74 | 99 | 9.89 | 9.26 | 4.95 | 9.83 | 5.53 | 10.33 | 4.64 | 11.15 | 97 | 7.49 | 12.11 | 99 | 8.68 | 7.40 | 99 | 2.36 |
|
| HYE | 1.47 | 7.48 | 107 | 9.04 | 93 | 10.81 | 9.41 | 3.68 | 9.99 | 5.69 | 10.64 | 6.28 | 11.54 | 91 | 8.05 | 12.30 | 91 | 6.69 | 7.83 | 95 | 2.37 |
|
| XBC18 | 4.79 | 6.51 | 93 | 8.61 | 102 | 9.29 | 9.05 | 3.72 | 9.56 | 4.50 | 10.22 | 5.48 | 11.17 | 101 | 7.03 | 11.77 | 100 | 4.29 | 7.16 | 100 | 2.32 |
|
| DISC | 8.77 | 6.36 | 91 | 8.82 | 107 | 14.29 | 9.20 | 4.12 | 9.76 | 6.11 | 10.41 | 6.85 | 11.26 | 104 | 8.16 | 11.98 | 105 | 6.88 | 7.02 | 100 | 2.71 |
|
| AC18 | 7.90 | 7.39 | 106 | 9.07 | 94 | 12.48 | 9.37 | 3.35 | 9.92 | 6.36 | 10.67 | 7.89 | 11.58 | 92 | 8.91 | 12.22 | 92 | 6.13 | 7.80 | 96 | 2.61 |
|
| AAR | 4.48 | 7.40 | 106 | 9.16 | 95 | 12.88 | 9.32 | 1.87 | 9.98 | 7.70 | 10.79 | 8.77 | 11.57 | 92 | 7.84 | 12.42 | 93 | 8.22 | 7.74 | 95 | 1.99 |
|
| ING | 4.56 | 7.18 | 103 | 9.30 | 100 | 11.98 | 9.30 | 0.00 | 9.89 | 5.41 | 10.91 | 8.71 | 11.93 | 98 | 8.51 | 12.30 | 95 | 2.95 | 7.63 | 97 | 2.25 |
|
| NUH | 4.54 | 7.14 | 102 | 8.95 | 96 | 11.39 | 9.23 | 2.95 | 9.82 | 6.33 | 10.56 | 7.34 | 11.58 | 95 | 6.16 | 12.18 | 95 | 3.62 | 7.59 | 97 | 2.31 |
|
| AAQ | 1.27 | 7.03 | 100 | 9.16 | 100 | 12.25 | 9.37 | 2.31 | 9.86 | 5.39 | 10.71 | 8.86 | 11.72 | 98 | 9.28 | 12.35 | 98 | 5.71 | 7.36 | 95 | 1.58 |
|
| WAH | 6.13 | 6.65 | 95 | 8.90 | 103 | 12.17 | 9.17 | 2.70 | 9.71 | 5.73 | 10.51 | 7.88 | 11.45 | 101 | 8.58 | 12.07 | 101 | 5.54 | 7.35 | 100 | 2.66 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| INH | 1.30 | 7.10 | 101 | 9.22 | 100 | 10.01 | 9.22 | 0.00 | 9.84 | 4.53 | 10.76 | 6.84 | 11.73 | 97 | 6.77 | 12.31 | 96 | 3.95 | 7.53 | 96 | 1.92 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| KRO | 7.94 | 7.47 | 107 | 9.08 | 94 | 13.89 | 9.23 | 1.82 | 9.80 | 6.89 | 10.71 | 10.34 | 11.75 | 93 | 10.14 | 12.24 | 91 | 4.73 | 7.83 | 95 | 2.84 |
|
| NUP | 2.58 | 7.08 | 101 | 9.08 | 99 | 14.13 | 9.13 | 1.01 | 9.72 | 5.57 | 10.68 | 9.60 | 11.67 | 97 | 9.00 | 12.28 | 96 | 5.30 | 7.48 | 96 | 1.70 |
|
| AHL | 10.83 | 7.40 | 106 | 9.09 | 94 | 13.32 | 9.24 | 1.79 | 9.81 | 6.40 | 10.72 | 9.87 | 11.74 | 93 | 9.85 | 12.23 | 92 | 4.49 | 7.77 | 95 | 2.74 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PODS3 | 8.36 | 7.32 | 105 | 9.09 | 96 | 12.70 | 9.28 | 2.02 | 9.87 | 6.42 | 10.71 | 8.61 | 11.66 | 94 | 8.54 | 12.29 | 93 | 5.55 | 7.72 | 96 | 2.68 |
|
| SUN | 5.19 | 7.56 | 108 | 9.32 | 95 | 14.06 | 9.32 | 0.00 | 9.91 | 6.43 | 10.96 | 10.87 | 11.96 | 93 | 9.59 | 12.41 | 91 | 4.22 | 7.95 | 96 | 2.25 |
|
| LUN | 6.04 | 7.33 | 105 | 9.23 | 97 | 13.16 | 9.23 | 0.00 | 9.82 | 6.26 | 10.83 | 11.04 | 11.82 | 95 | 9.54 | 12.33 | 93 | 4.86 | 7.74 | 96 | 2.47 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Meaning of symbols is explained in the text. The columns non-suitable for the LC analysis of lamotrigine according to the SST test are indicated in bold. The stationary phases non-suitable for the separation of the analytes according to the second Ph. Eur. recommendation are indicated in italics
Fig. 2LC analysis of the sample containing lamotrigine and impurities A–G at the concentration levels of 0.2 mg mL−1 for parent substance and 0.1 % for the related compounds performed on a HYP, b HYE, and c SODS1 column, respectively
Fig. 3Projection of the variables (a) and objects (b) onto the space of the first two PFs (PF1 and PF2) extracted from FA four column parameters provided by KUL test procedure for the 28 stationary phases studied
Fig. 4Two-dimensional FA plots of the variables (a) and objects (b) based on the retention parameters (t R and R s) of the analytes during column performance for the LC analysis of lamotrigine and its related substances